dc.contributorGonzalez-Lopez, L., Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Universidad de Guadalajara, Guadalajara, Mexico; Sanchez-Hernandez, J.D., Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Universidad de Guadalajara, Guadalajara, Mexico; Aguilar-Chavez, E.A.G., Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Universidad de Guadalajara, Guadalajara, Mexico; Cota-Sanchez, A.R., Department of Blood Chemistry, Centro M�dico Nacional de Occidente, IMMS, Guadalajara, Mexico; Lopez-Olivo, M.A., Anderson Hospital, Houston, TX, United States; Villa-Manzano, A.I., Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Universidad de Guadalajara, Guadalajara, Mexico; Ortega-Flores, R., Department of Blood Chemistry, Hospital General Regional 110, IMSS, Guadalajara, Mexico; Espinoza-Maga�a, G.L., Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico; Rojo-Contreras, W., Hospital General de Zona 6, Postgraduate Program of Medical Sciences, Universidad de Colima, Colima, Mexico; Cardona-Mu�oz, E.G., Department of Internal Medicine-Cardiology, Hospital General Regional 45, IMSS, Guadalajara, Mexico; Gamez-Nava, J.I., Section for Clinical Studies in Musculoskeletal and Autoimmune Diseases, Hospital de Especialidades, Universidad de Guadalajara, Guadalajara, Mexico, Av. Salto del Agua 2192 Col. Jardines del Country, Guadalajara, Jalisco CP 44210, Mexico
dc.creatorGonzalez-Lopez, L.
dc.creatorSanchez-Hernandez, J.D.
dc.creatorAguilar-Chavez, E.A.G.
dc.creatorCota-Sanchez, A.R.
dc.creatorLopez-Olivo, M.A.
dc.creatorVilla-Manzano, A.I.
dc.creatorOrtega-Flores, R.
dc.creatorEspinoza-Magana, G.L.
dc.creatorRojo-Contreras, W.
dc.creatorCardona-Munoz, E.G.
dc.creatorGamez-Nava, J.I.
dc.date.accessioned2015-09-15T18:08:13Z
dc.date.accessioned2023-07-04T02:13:51Z
dc.date.available2015-09-15T18:08:13Z
dc.date.available2023-07-04T02:13:51Z
dc.date.created2015-09-15T18:08:13Z
dc.date.issued2008
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-51649102976&partnerID=40&md5=659bcf6c9e33cbd53caba5f8bd09deed
dc.identifierhttp://hdl.handle.net/20.500.12104/42011
dc.identifier10.1007/s00296-008-0687-4
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7260799
dc.description.abstractWe evaluated the prevalence and characteristics associated with hyperhomocysteinemia in ankylosing spondylitis (AS). Ninety-seven patients with AS were compared with 97 controls. The assessment included clinical characteristics, disease activity (BASDAI), functioning (BASFI), history of drugs, and erythrocyte sedimentation rate (ESR). Total serum homocysteine (tHcy) was determined by fluorescence polarization immunoassay. A higher frequency of hyperhomocysteinemia (>15 ?mol/L) was observed in AS (12 vs. 1%, P = 0.002). In the multivariate analysis the risk for hyperhomocysteinemia was increased in patients with higher score of HAQ-S (OR = 5.27, 95% CI: 1.29-21.44) and higher ESR (OR = 1.09, 95% CI: 1.02-1.18). No statistical associations was observed between hyperhomocysteinemia with other variables including methotrexate or sulfasalazine utilization. In conclusion, this study found a significant prevalence of hyperhomocysteinemia in Mexican patients with AS mainly associated to a worst functional impairment. Further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients. � 2008 Springer-Verlag.
dc.relationScopus
dc.relationWOS
dc.relationRheumatology International
dc.relation28
dc.relation12
dc.relation1223
dc.relation1228
dc.titleHyperhomocysteinemia in ankylosing spondylitis: Prevalence and association with clinical variables
dc.typeArticle


Este ítem pertenece a la siguiente institución